Find clinical trials for COVID-19 in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections

Communicable Diseases

Coronavirus Infections

Pneumonia

Post-Acute COVID-19 Syndrome

Syndrome

Human Influenza

COVID-19 trials near Chicago, IL, USA:

Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

for infectious pneumonia acquired in the community (CAP), including COVID-19.Secondary objectives:- To determine the effect of repa...

Enrolling

Severe COVID-19

Infectious Pneumonia

Other: Placebo

Drug: Reparixin

Phase 3

Dompé

Chicago, Illinois, United States and 108 other locations

Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID...

Enrolling

Covid19

Drug: STRI Formula

Drug: Placebo

Phase 2

Eyecheck

Oak Forest, Illinois, United States and 12 other locations

Oscillation and Lung Expansion Therapy in Patients With COVID-19

A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19...

Enrolling

COVID-19

Oscillation and Lung Expansion

Device: MetaNeb® System

Hill-Rom

Evanston, Illinois, United States and 1 other location

A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2

A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or...

Active, not recruiting

COVID-19

SARS-CoV-2

Drug: Normal saline

Drug: VYD222

Phase 3

Invivyd

Oak Brook, Illinois, United States and 17 other locations

Study of LAU-7b for the Treatment of COVID-19 Disease in Adults (RESOLUTION)

A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patient...

Active, not recruiting

COVID-19 Disease

Drug: Placebo oral capsule

Drug: LAU-7b

Phase 2, Phase 3

Laurent Pharmaceuticals

Chicago, Illinois, United States and 28 other locations

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID...

Enrolling

COVID-19

Device: RD-X19

Device: Sham

EmitBio

Chicago, Illinois, United States and 47 other locations

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

and efficacy of MultiStem therapy in subjects with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to pathogens including COVID...

Enrolling

ARDS

Biological: Placebo

Biological: MultiStem

Phase 2, Phase 3

Athersys

Chicago, Illinois, United States and 3 other locations

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have =<2500 U/mL SARS-CoV-2 S antibody concentra...

Active, not recruiting

COVID-19

Kidney Transplant

Biological: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine

Phase 2

National Institute of Allergy and Infectious Diseases (NIAID)

Chicago, Illinois, United States and 5 other locations

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. (BOSS-002)

in treating high-risk participants who have tested positive for Covid-19. The main question[s] it aims to answer are:To evaluate th-...

Enrolling

COVID-19

Other: Placebo

Drug: NP-101

Phase 2

Novatek Pharmaceuticals

Berwyn, Illinois, United States and 3 other locations

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its...

Active, not recruiting

COVID-19

Biological: mRNA-1273.222

Biological: mRNA-1283.222

Phase 3